1-Month DAPT After Current-Generation DES PCI May Be Best for High-Bleeding-Risk Patients...

European Heart Journal 2026 Optimal Potassium Range in Heart Failure: 4.2–5.0 mmol/L *...

ACC/AHA 2026 First-Ever Guideline for Cardiovascular-Kidney-Metabolic (CKM) Syndrome A...

The Lancet / EuroPCR 2026 ANOCA, INOCA & MINOCA: Beyond...

A multicenter European study with prominent participation and first authorship by a...

Safer NSAID Choice for AF Patients Receiving DOACs Source: JAMA, June 3, 2026. TCTMD...

Single Versus Dual Antiplatelet Therapy After TAVR in Patients Without an Indication for...

NEJM / EAS 2026 – Heart-2 Trial VERVE-102, a one-time IV therapy designed to permanently...

EAS 2026 Highlights: During the ongoing EAS Congress 2026 in Athens (May 24–27,...

Can Tirofiban Improve 90-Day Outcomes After Poor Response to Stroke Thrombolysis? New...

 A new RNA-based Therapy (microRNA) Change Post-MI Remodeling? Phase 2 HF-REVERT trial...

ESC Heart Failure 2026 (Barcelona | May 17–20, 2026): Cardiac Glycosides Making a Comeback...